News and Trends 23 Nov 2022 FDA approves CSL gene therapy for hemophilia B CSL has revealed that the U.S. Food and Drug Administration (FDA) has approved HEMGENIX (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with hemophilia B. HEMGENIX is approved for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage or […] November 23, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2022 Achilles Therapeutics receives US patent for immunotherapies A U.S. patent has been granted to Achilles Therapeutics plc for the treatment of patients with an immunotherapy, including vaccine, antibody and autologous T cell therapy approaches, targeting clonal neoantigens identified using the Achilles Clonality Engine (ACE). ACE is a proprietary method for determining clonality of patient-specific mutations that drives the PELEUS bioinformatics platform. Clonal […] November 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2022 CatalYm raises €50M to boost solid tumors trial CatalYm has announced the close of a €50 million ($49 million) series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. The financing will support the clinical development of its […] November 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2022 Arecor to start second type 2 diabetes clinical trial Arecor Therapeutics plc says the BASG (Bundesamt für Sicherheit im Gesundheitswesen) has cleared the company’s clinical trial application (CTA) for AT278, an ultra-rapid acting, ultra-concentrated (500 U/mL) insulin candidate, in type 2 diabetic patients. The CTA approval means Arecor can start its second phase I clinical trial for AT278. AT278 has previously demonstrated a faster […] November 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2022 FogPharma raises $178M to target cancer U.S biotech company FogPharma has announced a $178 million series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, funds and accounts advised by T. Rowe Price Associates, Inc., Invus, Farallon Capital Management, […] November 21, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Startup Scout 21 Nov 2022 Osivax is designing future-proof influenza and Covid vaccines Viruses causing influenza and COVID-19 continually evolve to escape our vaccine protections. The French firm Osivax is developing vaccines that are harder for the viruses to evade. Many life-saving vaccines have been developed and approved to protect against viral infections including COVID-19 and influenza. Commercially available vaccines typically activate the production of antibodies against fragments […] November 21, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2022 Legend Biotech small cell lung cancer drug gets FDA ok for clinical development Legend Biotech Corporation has announced that the U.S. Food and Drug Administration (FDA) has cleared Legend Biotech’s investigational new drug (IND) application to proceed with the clinical development of LB2102, an investigational, autologous chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of adult patients with extensive stage small cell lung cancer (SCLC). LB2102 is […] November 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2022 Immorna cleared for mRNA-based Covid-19 vaccine study U.S. biotech company Immorna says the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to conduct a phase 1/2 multi-center study of JCXH-221, a lipid nanoparticle (LNP) complexed broadly protective mRNA vaccine against SARS-CoV-2 infection and diseases. The goal of the multi-center study is to assess the safety and immunogenicity […] November 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2022 New Replay HSV gene therapy company Telaria to focus on skin diseases Replay has announced the launch of Telaria, a herpes simplex virus (HSV) gene therapy company targeting rare skin diseases. It is the second of Replay’s product companies to leverage its high payload capacity HSV delivery vector, synHSV. Telaria’s co-founders are HSV scientists, entrepreneurs, and specialists in genetic skin diseases. In addition to Joe Glorioso, Telaria’s […] November 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2022 Agreement boosts mRNA manufacturing in Singapore RVAC Medicines Pte. Ltd., a messenger RNA (mRNA) technology platform company, and the Agency for Science, Technology and Research (A*STAR) have signed a research collaboration agreement to jointly study and develop solutions to build mRNA manufacturing and analytics capabilities in Singapore. RVAC and A*STAR will set up a joint laboratory based at A*STAR’s Bioprocessing Technology […] November 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2022 Genomic Data Infrastructure Ireland project to support discovery of genetic causes of disease RCSI University of Medicine and Health Sciences and FutureNeuro are co-leading, with University College Dublin, the Irish element of a new EU project to support the integration of genomics into healthcare and advance new treatments for patients. Jointly funded by the European Commission, under the Digital Europe Programme, and the Health Research Board (HRB), Genomic […] November 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2022 FMRP – the protein behind immunotherapy resistance Immunotherapy is a cutting-edge approach to treating cancer by turning the patient’s own immune system against their tumor. Despite success rates, immunotherapy has time and again met with a stubborn obstacle: tumor cells often evade the “radar” of immune cells seeking to destroy them. This in turn leads to treatment resistance, which in many cases […] November 21, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email